|6-氟-3-氧代-3,4-二氢吡嗪-2-酰胺|CsnPharm

CAS No.: 259793-96-9

法匹拉韦 Catalog No. CSN12666

Synonyms: T-705;T 705;Favilavir

Favipiravir is an anti-viral compound with activity against many RNA viruses and an RNA-directed RNA polymerase NS5B inhibitor.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis.
细胞研究

Cell Data

Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources
MDCK cells	-	Function assay	-	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	17194832
MDCK cells	-	Function assay	-	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	17194832
Vero cells	-	Function assay	7-8 days	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	17606691

动物研究

剂量

Mice: 37.5 mg/kg - 300 mg/kg^[3] (p.o.), 20 mg/kg^[4] (p.o.)

给药途径

p.o.

动物药代数据

Animal	Mice^[2]
Dose	100 mg/kg
Administration	p.o.
T_max	46.2 min (PICV-infected) 28.5 min (Sham-infected)
T_1/2β	53.4 min (PICV-infected) 40.3 min (Sham-infected)
C_max	40.9 μg/ml (PICV-infected) 81.5 μg/ml (Sham-infected)
T_1/2α	20.6 min (PICV-infected) 11.1 min (Sham-infected)
AUC	4339.8 μg·min/ml (PICV-infected) 7740.8 μg·min/ml (Sham-infected)

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01728753	Influenza	Phase 1 Phase 2	Completed	-	United States, Florida ... more >> Miami Research Associates Miami, Florida, United States, 33143 Collapse <<
NCT02662855	Ebola Virus Disease	Phase 2	Completed	-	-
NCT01068912	Influenza	Phase 2	Completed	-	-

更多
参考文献

[1] Tani H, Komeno T, et al. Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration. PLoS One. 2018;13(10):e0206416.
[2] Gowen BB, Sefing EJ, et al. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015 Sep;121:132-7.
[3] Bixler SL, Bocan TM, et al. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antiviral Res. 2018 Mar;151:50-54.
[4] Tarbet EB, Maekawa M, et al. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 2012 Apr;94(1):103-10.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 6.3654 mL
- 31.8269 mL
- 63.6537 mL
- 5 mM
- 1.2731 mL
- 6.3654 mL
- 12.7307 mL
- 10 mM
- 0.6365 mL
- 3.1827 mL
- 6.3654 mL

技术信息

CAS号

259793-96-9

储存条件

粉末: Inert atmosphere,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C5H4FN3O2

运输

蓝冰

分子量

157.10

别名

T-705;T 705;Favilavir;Avigan

溶解度

DMSO	110.0 mg/mL (700.2 mM) warming
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01728753	Influenza	Phase 1 Phase 2	Completed	-	United States, Florida ... more >> Miami Research Associates Miami, Florida, United States, 33143 Collapse <<
NCT02662855	Ebola Virus Disease	Phase 2	Completed	-	-
NCT01068912	Influenza	Phase 2	Completed	-	-
NCT02008344	Influenza	Phase 3	Completed	-	-
NCT02026349	Influenza	Phase 3	Completed	-	-
NCT02739477	Ebola Virus Survivor	Phase 2	Terminated(End date of epidemi... more >>c) Collapse <<	-	Guinea ... more >> Conakry Conakry, Guinea Nzérékoré Nzérékoré, Guinea Collapse <<
NCT03394209	Influenza, Human ... more >> Critical Illness Influenza Collapse <<	Phase 2	Recruiting	December 10, 2018	China ... more >> China-Japan Friendship Hospital Recruiting Beijing, China, 100029 Contact: Bin Cao, Ph.D 86 010 84206264 caobin_ben@163.com Contact: Yeming Wang, Ph.D 86 18810663558 wwyymm_love@163.com Principal Investigator: Bin Cao, Ph.D Collapse <<
NCT02329054	Ebola Virus Disease	Phase 2	Completed	-	Guinea ... more >> The caregivers treatment center Conakry, Guinea MSF Ebola treatment centre Gueckedou, Guinea French Red Cross Ebola care center Macenta, Guinea ALIMA Ebola care center Nzerekore, Guinea Collapse <<
NCT01068912	-	-	Completed	-	-
NCT01419457	Healthy Hepat... more >>ic Impairment Collapse <<	Phase 1	Completed	-	United States, Florida ... more >> University of Miami Miami, Florida, United States Orlando Clinical Research Center Orlando, Florida, United States Collapse <<

法匹拉韦 Catalog No. CSN12666

靶点选择性

请登录您的专属账户

确认信息